Phaseline

Companies › Pharmasoft

Pharmasoft: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 4; Neurology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Glycine
Glycine receptor agonist
GLRA1Phase 4Ischemic StrokeApr 2027
Mexidol
Antioxidant and neuroprotective agent
–Phase 4Ischemic StrokeApr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07575984MexidolPhase 4Ischemic StrokeNeurologyApr 2027
NCT07575984GlycinePhase 4Ischemic StrokeNeurologyApr 2027

Targets

GLRA1 (1)

Companies with the same targets

NeuroRx Sedana Medical

Companies built like this

Suven Life Sciences Bigespas JYAMS PET Research & Development Longboard Pharmaceuticals TriGemX Bio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.